Targeting TROP2 with Antibody-Drug Conjugates in NSCLC: Integrating Evidence, Overcoming Hurdles, & Optimizing Patient Care

Jointly provided by Postgraduate Healthcare Education, LLC (PHE) and Postgraduate Institute for Medicine (PIM).

This activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.

Registration & Dates for Activities

Thursday, November 21, 2024
3:00-4:15 PM ET

FACULTY

Val R. Adams, PharmD, FCCP, FHOPA, BCOP
Associate Professor
Department of Pharmacy Practice and Science
College of Pharmacy
University of Kentucky
Lexington, KY

Marianne J. Davies DNP, ACNP, AOCNP, FAAN
Oncology Nurse Practitioner & Care Signature Manager
Medical Oncology
Yale New Haven Hospital at Yale Cancer Center
New Haven, CT

Beth Sandy, MSN, CRNP, FAPO
Thoracic Oncology Nurse Practitioner
Abramson Cancer Center
University of Pennsylvania
Philadelphia, PA

FINANCIAL DISCLOSURE

Dr. Adams has no relevant affiliations or financial relationships with a commercial interest to disclose.

Dr. Davies has no actual or potential conflicts of interest in relation to this program.

Ms. Sandy has disclosed that she serves on the speaker’s bureau for Amgen, AstraZeneca, Eli Lilly, Jazz Pharmaceuticals, Merck & Co., and Takeda; and as a consultant/advisory board member for Janssen and Pfizer.

The clinical reviewer, Lisa Holle, PharmD, BCOP, FHOPA has no actual or potential conflicts of interest in relation to this program.

Susanne Kwas, MSHF, BSN, RN, Robin Soboti, RPh, and Susan R. Grady, MSN, RN as well as the planners, managers, and other individuals, not previously disclosed, who are in a position to control the content of Postgraduate Healthcare Education (PHE) continuing education (CE) activities hereby state that they have no relevant conflicts of interest and no financial relationships or relationships to products or devices during the past 12 months to disclose in relation to this activity. PHE is committed to providing participants with a quality learning experience and to improve clinical outcomes without promoting the financial interests of a proprietary business.

All relevant financial relationships have been mitigated.

ACCREDITATION STATEMENTS

PHARMACY
Postgraduate Healthcare Education, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
UAN: 0430-9999-24-104-L01-P
Credits: 1.25 hour (0.125 ceu)

Type of Activity: Application
Media: Internet

Fee Information: There is no fee. This is a free continuing education activity.
Estimated time to complete activity: 75 minutes

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Postgraduate Healthcare Education. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.25 contact hours. Designated for 1.0 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

TARGET AUDIENCE

This activity has been designed to meet the needs of Oncology Pharmacists, Nurse and Nurse Practitioners.

HOW TO EARN CREDIT

Participants must 1) read the learning objectives and faculty disclosures; 2) attend and participate in the live webinar; and 3) complete the evaluation form directly after the event with a maximum of within 60 days of attending the live session. To answer the questions, click on your selected choice for each answer then proceed to the next question. To receive Credit, you must provide your date of birth and NABP number. All Credit information will be uploaded into CPE monitor within 30 days.

GOAL

The goal of this educational activity is to equip and empower oncology pharmacists, nurses, and nurse practitioners with the knowledge, confidence, and competence, to ensure integration of the latest evidence and clinical best practices for managing TROP2-overexpressed NSCLC with novel antibody-drug conjugates, thus optimizing patient care and treatment outcomes.

LEARNING OBJECTIVES

At the conclusion of the activity, pharmacists and pharmacy technicians will be able to:

• Describe the prevalence and pathophysiology of trophoblast cell surface antigen 2 (TROP2) in NSCLC, characterizing its emerging promise as a treatment target for antibody-drug conjugates (ADCs)
• Evaluate the established and evolving evidentiary base for TROP2-targeted ADCs within the NSCLC management paradigm
• Develop evidence-based care plans for NSCLC patients receiving ADCs, with an emphasis on the recognition, mitigation, and management of treatment-related toxicities

REQUIRED COMPUTER HARDWARE/SOFTWARE

Please ensure the computer system you plan to use meets the following minimum requirements:

• Operating System: Windows 98 or higher & Macintosh 2.2 or higher
• Internet Browser (Mac & Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher, & Opera 5 or higher
• Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible
• Peripherals: Computer speakers or headphones
• Monitor Screen Resolution: 320 x 480 or higher
• Media Viewing Requirements: Adobe Reader, Microsoft PowerPoint, Flash Player & HTML5

Disclosure of Unlabeled Use and Disclaimer

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Postgraduate Healthcare Education, LLC, Postgraduate Institute of Medicine, AstraZeneca or Daichi Sankyo, Inc. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions, and possible contraindications on dangers in use, (review of any applicable manufacturer's product information) and comparison with recommendations of other authorities.

The author, sponsor, and publisher of this continuing education activity have made all reasonable efforts to ensure that all information contained herein is accurate in accordance with the latest available scientific knowledge at the time of acceptance for publication. However, because information regarding drugs (their administration, dosages, contraindications, adverse reactions, interactions, special warnings, precautions, etc.) is subject to constant change, the reader is advised to check the manufacturer's package insert for information concerning recommended dosages and potential problems and cautions prior to dispensing or administering the drug. Special precautions should be taken when a drug is new, or highly toxic, or is unfamiliar to the dispenser or administrant. This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the U.S. Food and Drug Administration (FDA). Neither the publisher nor sponsor promotes the use of any agent outside of approved labeling. Statements made in this activity have not been evaluated by the FDA.